Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Antigen Receptor	NCIT_C126107	[A cell-surface receptor found on T-cells or B-cells that recognize specific antigenic peptides. Each cell naturally produces a unique receptor that binds to a unique epitope on a target cell.]
Metastatic Urothelial Carcinoma	NCIT_C126109	[An urothelial carcinoma which has spread from the original site of growth to another anatomic site.]
Metastatic Transitional Cell Carcinoma	NCIT_C129828	[A transitional cell carcinoma which has spread from the original site of growth to another anatomic site.]
Metastatic Genitourinary System Carcinoma	NCIT_C146893	[A carcinoma that arises from the genitourinary system and has metastasized to other anatomic sites.]
Urothelial Carcinoma	NCIT_C4030	[A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis). It is frequently papillary.]
Gene Modification	NCIT_C126104	[Any gene manipulation method used to generate a product with an altered sequence, structure, or conformation.]
Tinostamustine	NCIT_C126105	[An alkylating histone-deacetylase inhibitor (HDACi) fusion molecule composed of the alkylating agent bendamustine fused to the pan-HDACi vorinostat, with potential bi-functional antineoplastic activity. Upon administration of tinostamustine the vorinostat moiety targets and binds to HDACs. This leads to an accumulation of highly acetylated histones, which results in an induction of chromatin remodeling, a modulation of gene expression, an inhibition of tumor cell division and the induction of tumor cell apoptosis. The bendamustine moiety binds to, alkylates and crosslinks macromolecules, inhibiting DNA, RNA and protein synthesis, which also results in tumor cell apoptosis. Thus, tinostamustine shows superior efficacy compared to the activity of either agent alone. In addition, the inhibition of HDAC6 activity by tinostamustine induces the activation of inositol-requiring enzyme 1 (IRE-1), the key regulatory protein for the unfolded protein response (UPR). Induction of the UPR increases the sensitivity of certain cancer cell types to certain chemotherapeutic agents, such as proteasome inhibitors. Therefore, tinostamustine may work synergistically with proteasome inhibitors. HDACs, enzymes that deacetylate chromatin histone proteins, are overexpressed in various cancers and play a key role in proliferation and resistance of tumor cells.]
Antineoplastic Alkylating Agent	NCIT_C1590	[An antineoplastic agent that replaces hydrogen atom(s) in nucleophilic moieties with alky radical(s), hindering proper function. Alkylating agents exhibit cytotoxic effects through the alkylation of DNA, resulting in strand cross-linking, ultimately inhibiting DNA replication and cancer cell growth.]
DNA Intercalation	NCIT_C40492	[DNA Intercalation involves insertion by covalent linkage of a molecule into the double-stranded deoxyribonucleotide polymer between the internal purine and pyrimidine base pairs stacked one on another perpendicular to the double helix axis.]
DNA Replication Inhibition	NCIT_C40828	[DNA Replication Inhibition involves interference with, or restraint of, the activities of biologic molecules or complexes involved in the process by which the two strands of a DNA double helix separate and each strand acts as a template for the synthesis of a complementary strand by specific base pairing.]
DNA Crosslinking	NCIT_C25827	[DNA Crosslinking involves the formation of a covalent bond between two bases on DNA. (NCI)]
Fluorine F 18 Clofarabine	NCIT_C126106	[A radioconjugate composed of the nucleoside analog and deoxycytidine kinase (DCK)-dependent pro-drug clofarabine (Cl-F-ara-A) linked to the radioisotope fluorine F 18, with potential imaging activity using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 clofarabine, the clofarabine moiety is preferentially taken up by and accumulates in cells with dysregulated nucleoside metabolism, including tumor cells expressing high levels of DCK. The clofarabine moiety is phosphorylated by DCK into its active triphosphate form, Cl-F-ara-ATP. The 18F moiety can be visualized by PET imaging. As many nucleoside analog prodrugs are chemotherapeutic agents that require DCK for their phosphorylation and activation, fluorine F 18 clofarabine can potentially be used as a marker to measure DCK activity and to predict the chemotherapeutic efficacy of DCK-dependent prodrugs. DCK, a rate-limiting enzyme in the deoxyribonucleoside salvage pathway for DNA synthesis, is overexpressed in certain solid tumors, lymphoid and myeloid malignancies and certain immune cells, such as proliferating T-lymphocytes. Compared to other nucleoside analogs, clofarabine is not susceptible to deamination by cytidine deaminase (CDA).]
Cell Surface Receptor	NCIT_C17067	[A receptor protein that is localized to the plasma membrane and may have exposure to the extracellular milieu.]
Scopoletin	NCIT_C126100	[A coumarin compound found in several plants including those in the genus Scopolia and the genus Brunfelsia, as well as chicory (Cichorium), redstem wormwood (Artemisia scoparia), stinging nettle (Urtica dioica), passion flower (Passiflora), noni (Morinda citrifolia fruit) and European black nightshade (Solanum nigrum) that is comprised of umbelliferone with a methoxy group substituent at position 6. Scopoletin is used to standardize and establish pharmacokinetic properties for products derived from the plants that produce it, such as noni extract. Although the mechanism(s) of action have not yet been established, this agent has potential antineoplastic, antidopaminergic, antioxidant, anti-inflammatory and anticholinesterase effects.]
Coumarin Compound	NCIT_C45597	[A heterocyclic compound with anticoagulant activity. It is found naturally in many plants or can be prepared synthetically. A coumarin compound contains the 1,2-benzopyrone structure.]
Hurthle Cell Metaplasia	NCIT_C35567
Not Available	NCIT_C126101	[The desired information is not available.]
Astler-Coller B1 Colon Carcinoma	NCIT_C35568
Astler-Coller B1 Colorectal Carcinoma	NCIT_C36204
Chimeric Antigen Receptor T-Cell Therapy	NCIT_C126102	[Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.]